Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors

Inclusion Criteria: 1. Patients voluntarily signed informed consent, and be able to complete the trial according to the requirement of the scheme; 2. Aged 18-80, male or female; 3. The clinical diagnosis was gastric cancer, esophageal cancer and pancreatic cancer; 4. Patients with biopsy-proven CLDN18.2 positive; 5. Patients diagnosed with solid tumors confirmed by histopathology or cytology test; 6. At least two measurable solid lesions has been examined by 18F-FDG PET/CT (RECIST1.1 standard); 7. ECOG score ≤ 0\~3; Life expectancy of at least 3 months; 8. ALT, AST shall not exceed 3 times of the normal upper limit; Bun, Cr not exceed 1.5 times of the normal upper limit. 9. Other routine examinations are within the normal range or considered acceptable by the researchers. Exclusion Criteria: 1. Recovery from major trauma (including surgery) within 4 weeks prior to study treatment; 2. Patients with systemic or locally severe infections, or other serious coexisting diseases; 3. Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; 4. Patients with autoimmune diseases, including rheumatoid arthritis; 5. Inadequate control of arrhythmias, including atrial fibrillation; 6. Uncontrolled hypertension; 7. Patients with allergies or allergies to any component of the imaging agent or antibody; 8. Patients who cannot undergo PET/CT imaging scan; 9. Syphilis, HBV, HCV, or HIV positive subjects; 10. Male and female subjects of reproductive age cannot take effective contraceptive measures; 11. Pregnant or lactating women; 12. Patients with a history of mental illness or related conditions; 13. Other subjects considered unsuitable by researchers.